Agilent Technologies grows life-
science business with strategic acquisitions in next-generation sequencing and automated analytical solutions for pharma
Valeant shows both its amiable and hostile sides with an agreement to acquire Australia’s iNova and a hostile bid to take over U.S. company ISTA
Pharmaceuticals
Company will collaborate with Chungnam National University in Korea to develop reference site on
glycomics methods for biopharmaceuticals and biosimilars
According to the Centers for Disease
Control and Prevention, the top 10 cancer types are in the solid tumor category; today, the priority is likely even higher. Thus, there are clear unmet
medical needs, and the development of new, cost-efficient and patient-friendly treatments remain a high priority for both the healthcare community and
patients.
A quick Google search for the phrase “outcomes-based medicine” yields results in the tens
of thousands. When you look at a lot of these results, however, the focus is on scientific method and not, ironically, on outcomes—which is the point of
medicine, isn’t it?
From publishing our single newspaper in January 2005 to celebrating our
eighth year in 2012, ddn continues to produce many vehicles that disseminate the news.
We’ve updated our Privacy Policy to make it clearer how we use your personal data. Please read our Cookie Policy to learn how we use cookies to provide you with a better experience.